Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK 1430306 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 17.2M shares as of Aug 7, 2026 (10-Q). Share count fell from 186.9M to 6.4M between Nov 12, 2024 and Mar 17, 2025, a pattern consistent with a reverse split (roughly 1-for-29); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Warrant1 | 615,025 | $0.001 | — | — |
| Warrant5 | 10,884 | $1056 | — | — |
| Warrant7 | 5,758 | $2720 | — | — |
| Warrant2 | 4,585 | $1056 | — | — |
| Warrant3 | 2,782 | $1056 | — | — |
| Warrant4 | 2,172 | $1056 | — | — |
| Warrant6 | 36 | $1600 | — | — |
| Warrant8 | 22 | $3200 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 10, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 641,264 underlying shares, as reported Jun 30, 2026 (10-Q).
Reported exercise price: $4.25 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 17.8M = 17.2M O/S + 641,264 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 10, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 17.2M | Aug 7, 2026 |
| + Warrant1 (if exercised) | 615,025 | Jun 30, 2026 |
| + Warrant5 (if exercised) | 10,884 | Jun 30, 2026 |
| + Warrant7 (if exercised) | 5,758 | Jun 30, 2026 |
| + Warrant2 (if exercised) | 4,585 | Jun 30, 2026 |
| + Warrant3 (if exercised) | 2,782 | Jun 30, 2026 |
| + Warrant4 (if exercised) | 2,172 | Jun 30, 2026 |
| + Warrant6 (if exercised) | 36 | Jun 30, 2026 |
| + Warrant8 (if exercised) | 22 | Jun 30, 2026 |
| Fully diluted estimate | 17.8M | +3.7% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 2 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full TNXP workspace